767 related articles for article (PubMed ID: 16337092)
21. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
Morale MC; L'Episcopo F; Tirolo C; Giaquinta G; Caniglia S; Testa N; Arcieri P; Serra PA; Lupo G; Alberghina M; Harada N; Honda S; Panzica GC; Marchetti B
Brain Res Rev; 2008 Mar; 57(2):431-43. PubMed ID: 18063054
[TBL] [Abstract][Full Text] [Related]
22. Inflammation in Parkinson's disease: causative or epiphenomenal?
Hald A; Van Beek J; Lotharius J
Subcell Biochem; 2007; 42():249-79. PubMed ID: 17612055
[TBL] [Abstract][Full Text] [Related]
23. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
24. [Inflammation and Parkinson's disease].
Barcia González C; Herrero Ezquerro MT
Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
[TBL] [Abstract][Full Text] [Related]
25. Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage.
Liu B; Qin L; Yang SN; Wilson BC; Liu Y; Hong JS
J Pharmacol Exp Ther; 2001 Sep; 298(3):1133-41. PubMed ID: 11504811
[TBL] [Abstract][Full Text] [Related]
26. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G
J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027
[TBL] [Abstract][Full Text] [Related]
27. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
28. Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
Saavedra A; Baltazar G; Santos P; Carvalho CM; Duarte EP
Neurobiol Dis; 2006 Sep; 23(3):533-42. PubMed ID: 16766196
[TBL] [Abstract][Full Text] [Related]
29. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
30. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures.
Tian YY; An LJ; Jiang L; Duan YL; Chen J; Jiang B
Life Sci; 2006 Dec; 80(3):193-9. PubMed ID: 17049947
[TBL] [Abstract][Full Text] [Related]
31. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
[TBL] [Abstract][Full Text] [Related]
32. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease.
Gao HM; Liu B; Zhang W; Hong JS
FASEB J; 2003 Oct; 17(13):1957-9. PubMed ID: 12923073
[TBL] [Abstract][Full Text] [Related]
33. Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease.
Tsang F; Soong TW
IUBMB Life; 2003 Jun; 55(6):323-7. PubMed ID: 12938734
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
35. Dopaminergic neurons.
Chinta SJ; Andersen JK
Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
[TBL] [Abstract][Full Text] [Related]
36. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Izal-Azcárate A; Belzunegui S; Marcilla I; López B; Luquin MR
J Neuropathol Exp Neurol; 2009 Sep; 68(9):977-84. PubMed ID: 19680145
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide and reactive oxygen species in Parkinson's disease.
Tieu K; Ischiropoulos H; Przedborski S
IUBMB Life; 2003 Jun; 55(6):329-35. PubMed ID: 12938735
[TBL] [Abstract][Full Text] [Related]
38. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease.
Hirsch EC; Hunot S; Damier P; Brugg B; Faucheux BA; Michel PP; Ruberg M; Muriel MP; Mouatt-Prigent A; Agid Y
Adv Neurol; 1999; 80():9-18. PubMed ID: 10410697
[No Abstract] [Full Text] [Related]
39. Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.
Mena MA; García de Yébenes J
Neuroscientist; 2008 Dec; 14(6):544-60. PubMed ID: 19029058
[TBL] [Abstract][Full Text] [Related]
40. Neuron-glia interactions as therapeutic targets in neurodegeneration.
Salmina AB
J Alzheimers Dis; 2009; 16(3):485-502. PubMed ID: 19276541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
